Antitumor activity according to IRC and investigator in the full analysis set
| Response | Per IRC (N=156) | Per investigator (N=156) |
| Best overall response, n (%) | ||
| CR | 2 (1.3) | 2 (1.3) |
| PR | 42 (26.9) | 35 (22.4) |
| SD | 41 (26.3) | 47 (30.1) |
| PD | 67 (42.9) | 67 (42.9) |
| NA | 4 (2.6) | 5 (3.2) |
| ORR, n (%) (95% CI) | 44 (28.2) (21.3 to 36.0) | 37 (23.7) (17.3 to 31.2) |
| DCR, n (%) (95% CI) | 85 (54.5) (46.3 to 62.5) | 84 (53.8) (45.7 to 61.9) |
| DOR, median (95% CI) | NR (9.5 to NR) | NR (13.0 to NR) |
| TTR (weeks), median (range) | 8.3 (7.3–40.7) | 8.3 (7.1–56.0) |
CR, complete response; DCR, disease control rate; DOR, duration of response; IRC, independent review committee; NA, not assessable; NR, not reached; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TTR, time to response.